Table 3.
Comparison of outcomes across cohorts
| 1989-1994, probability (95% CI) | 1995-2000, probability (95% CI) | 2001-2005, probability (95% CI) | P | |
|---|---|---|---|---|
| Acute GVHD (grades II-IV) at 100 d* | 29 (24-34) | 34 (29-39) | 35 (30-40) | .196‖ |
| Chronic GVHD† | ||||
| At 1 y | 32 (27-37) | 28 (23-33) | 46 (41-51) | < .001‖ |
| At 3 y | 33 (28-38) | 30 (25-34) | 49 (44-55) | < .001‖ |
| At 5 y | 33 (28-38) | 30 (25-34) | 51 (46-57) | < .001‖ |
| 100-day mortality‡ | 33 (28-38) | 29 (24-33) | 17 (14-21) | < .001‖ |
| Treatment-related mortality§ | ||||
| At 1 y | 36 (31-41) | 42 (37-47) | 22 (18-26) | < .001‖ |
| At 3 y | 40 (35-45) | 45 (40-50) | 27 (23-31) | < .001‖ |
| At 5 y | 40 (35-45) | 46 (41-51) | 28 (23-32) | < .001‖ |
| Relapse/progression§ | ||||
| At 1 y | 27 (22-31) | 19 (16-24) | 33 (29-37) | < .001‖ |
| At 3 y | 36 (31-41) | 28 (23-32) | 48 (43-53) | < .001‖ |
| At 5 y | 39 (33-44) | 32 (27-37) | 58 (51-64) | < .001‖ |
| PFS§ | .315¶ | |||
| At 1 y | 37 (32-43) | 39 (34-44) | 46 (41-50) | .035‖ |
| At 3 y | 24 (20-29) | 28 (23-32) | 25 (20-29) | .555‖ |
| At 5 y | 21 (17-26) | 22 (18-26) | 14 (9-20) | .084‖ |
| OS§ | .014¶ | |||
| At 1 y | 50 (45-56) | 49 (44-54) | 63 (59-67) | < .001‖ |
| At 3 y | 36 (31-41) | 36 (31-41) | 42 (37-47) | .199‖ |
| At 5 y | 30 (25-35) | 30 (26-35) | 29 (23-35) | .918‖ |
*
Cohort 1989-1994 (n = 342), 1995-2000 (n = 376), and 2001-2005 (n = 487).
†
Cohort 1989-1994 (n = 339), 1995-2000 (n = 373), and 2001-2005 (n = 475).
‡
Cohort 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 483).
§
Cohort 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488).
‖
Pointwise P value, which one is used in article.
¶
Determined with log-rank test.